Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04299438
Other study ID # 834760
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date July 14, 2020
Est. completion date July 15, 2022

Study information

Verified date August 2023
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A double-blind placebo controlled randomized trial comparing cesarean delivery rates in women given IV propranolol versus placebo for treatment of prolonged labor.


Description:

A double-blind placebo controlled randomized trial comparing cesarean delivery rates in 326 women given IV propranolol (2 mg with one possible repeat dose greater than 2 hours later) versus IV placebo for treatment of prolonged labor.


Recruitment information / eligibility

Status Terminated
Enrollment 164
Est. completion date July 15, 2022
Est. primary completion date June 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 16 Years and older
Eligibility Inclusion Criteria: English-speaking >= 36 weeks gestation Singleton pregnancy Vertex presentation No contraindication to a vaginal delivery Meets at least one study criteria for prolonged labor: 1. cervical dilation <6 cm after =8 hours with ruptured membranes and receiving oxytocin OR 2. cervical dilation >=6 cm and <1 cm dilation change over =2 hours with ruptured membranes and receiving oxytocin Exclusion Criteria: Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol for hypertension control Receiving other beta blocker Maternal heart rate < 70 beats per minute, systolic blood pressure <90 mmHg, or diastolic blood pressure <50 mmHg on two sets of vital signs in the 1 hour prior to study drug administration: given that bradycardia and hypotension are possible side effects of propranolol History of any form of asthma: as this is a contraindication to beta blocker use Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia in the neonate Any cardiac condition for which ß blockade is contraindicated (cardiogenic shock, sinus bradycardia, and greater than first degree heart block) Known hypersensitivity to propranolol Intrauterine fetal demise since different labor protocols are used in these women Major fetal congenital anomaly since rate of cesarean may be inherently different in these women, unrelated to labor

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Propranolol Hydrochloride
2mg/mL vials
Other:
Saline
0.9% saline in vials matching the vials of the active drug

Locations

Country Name City State
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Pennsylvania Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Lisa Levine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mode of Delivery Number of participants with a cesarean delivery From enrollment into the trial until delivery.
Secondary Length of Labor Time in hours from start of labor or induction of labor to delivery hours from start of labor or induction of labor to time of delivery
Secondary Postpartum Hemorrhage Amount of blood loss measured in mL from time of delivery through hospital discharge, usually 2-4 days
Secondary Chorioamnionitis Number of participants with chorioamnionitis from start of labor through delivery
Secondary Maternal Morbidity Number of participants with 1 or more of the following: blood transfusion, endometritis, wound infection, venous thromboembolism, hysterectomy, ICU admission, readmission, death from delivery through 4 weeks postpartum
Secondary Neonatal Morbidity Number of participants with 1 or more of the following: Intensive care nursery admission >48, blood transfusion, hypoxic-ischemic encephalopathy, intraventricular hemorrhage grade 3 or 4, neonatal head cooling, severe respiratory distress syndrome, necrotizing enterocolitis, sepsis, death from delivery through hospital discharge, usually 2-4 days
See also
  Status Clinical Trial Phase
Completed NCT01542151 - Effects of Sleep, Fatigue, and Timing of Post-dates Inductions Among Nulliparas N/A
Completed NCT02916082 - Cervical Length Pre-induction as a Tool to Predict Vaginal Birth N/A
Recruiting NCT03607929 - HIDRATA Study: Efficacy of a Hydration Protocol in Nulliparous Women During Labor N/A
Not yet recruiting NCT04307199 - Membrane Sweeping to Prevent Post-term Pregnancy: The MILO Study N/A
Completed NCT01140971 - Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor N/A
Recruiting NCT02255903 - Middle Cerebral To Umbilical Artery Doppler Ratio And Amniotic Fluid Volume Measurement In Post-date Pregnancies in King Khalid Military Central City
Not yet recruiting NCT02680093 - Birth Rate in Conservative Monitoring of Pregnancy Beyond the Date of Birth. N/A